


**AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows.

**Listing of Claims:**

Claims 1-27. (Canceled)

28. (Currently Amended) A compound of the formula I:



I

wherein:

R<sup>1</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
- (4) -OC<sub>1</sub>-6alkyl,
- (5) -S(O)<sub>m</sub>-C<sub>1</sub>-6alkyl, wherein m is selected from 0, 1 and 2,
- (6) -CO<sub>2</sub>R<sup>9</sup>, wherein R<sup>9</sup> is independently selected from:
  - (a) hydrogen,
  - (b) -C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
  - (c) benzyl, and
  - (d) phenyl,
- (7) -NR<sup>10</sup>R<sup>11</sup>, wherein R<sup>10</sup> and R<sup>11</sup> are independently selected from:
  - (a) hydrogen,
  - (b) -C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
  - (c) -C<sub>5</sub>-6cycloalkyl,
  - (d) benzyl,
  - (e) phenyl,
  - (f) -S(O)<sub>2</sub>-C<sub>1</sub>-6alkyl,
  - (g) -S(O)<sub>2</sub>-benzyl, and
  - (h) -S(O)<sub>2</sub>-phenyl,

- (8)  $-S(O)_2-NR^{10}R^{11}$ ,
- (9) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a)  $-C_{1-6}$ alkyl,
  - (b)  $-O-C_{1-6}$ alkyl,
  - (c) halo,
  - (d) hydroxy,
  - (e) trifluoromethyl, and
  - (f)  $-OCF_3$ ;

$R^3$  is selected from the group consisting of:

- (1)  $C_{1-6}$ alkyl, which is substituted with halogen, hydroxyl or phenyl,
- (2)  $C_{3-7}$ cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
- (3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a)  $-C_{1-6}$ alkyl, which is unsubstituted or substituted with  $-NR^{10}R^{11}$ ,
  - (b)  $-O-C_{1-6}$ alkyl,
  - (c) halo,
  - (d) hydroxy,
  - (e) trifluoromethyl,
  - (f)  $-OCF_3$ ;
  - (g)  $-CO_2R^9$ ,
  - (h)  $-NR^{10}R^{11}$ ,
  - (i)  $-C(O)NR^{10}R^{11}$ , and
  - (j)  $-NO_2$ ,
- (4) heterocycle, wherein heterocycle is selected from:  
benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl,

dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

- (a) -C<sub>1-6</sub>alkyl,
- (b) -O-C<sub>1-6</sub>alkyl,
- (c) halo,
- (d) hydroxy,
- (e) phenyl,
- (f) trifluoromethyl,
- (g) -OCF<sub>3</sub>;
- (h) -CO<sub>2</sub>R<sup>9</sup>,
- (i) -NR<sup>10</sup>R<sup>11</sup>, and
- (j) -CONR<sup>10</sup>R<sup>11</sup>;

R<sup>4</sup> is selected from the group consisting of:

- (1) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
- (2) C<sub>3-7</sub>cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
- (3) phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:
  - (a) -C<sub>1-6</sub>alkyl,
  - (b) -O-C<sub>1-6</sub>alkyl,
  - (c) halo,
  - (d) hydroxy,
  - (e) trifluoromethyl,
  - (f) -OCF<sub>3</sub>,
  - (g) -CO<sub>2</sub>R<sup>9</sup>,
  - (h) -NR<sup>10</sup>R<sup>11</sup>,
  - (i) -CONR<sup>10</sup>R<sup>11</sup>, and
  - (j) -NO<sub>2</sub>;
- (4) heterocycle, wherein heterocycle is selected from:

benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolyl, furanyl, imidazolyl, indolyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolyl, quinolyl, quinoxalyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof, which is unsubstituted or substituted with one or more substituents independently selected from:

- (a) -C<sub>1-6</sub>alkyl,
- (b) -O-C<sub>1-6</sub>alkyl,
- (c) halo,
- (d) hydroxy,
- (e) phenyl,
- (f) trifluoromethyl,
- (g) -OCF<sub>3</sub>,
- (h) -CO<sub>2</sub>R<sup>9</sup>,
- (i) -NR<sup>10</sup>R<sup>11</sup>, and
- (j) -CONR<sup>10</sup>R<sup>11</sup>;

or wherein R<sup>4</sup> and R<sup>5</sup> are joined together to form a phthalimidyl, succinimidyl or glutamidyl ring, which is unsubstituted or substituted with one or more substituents independently selected from the definitions of R<sup>1-2</sup>;

R<sup>2</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) -C<sub>1-6</sub>alkyl,
- (3) -O-C<sub>1-6</sub>alkyl,
- (4) halo,

- (5) hydroxyl,  
(6) -NO<sub>2</sub>, and  
(7) phenyl;

R<sup>5</sup> and R<sup>6</sup> are independently selected from the group consisting of:

- (1) hydrogen, and  
(2) C<sub>1-6</sub>alkyl;


n is an integer selected from 1, 2 and 3;

with the proviso that the compound of formula I is not:

N-[4-chloro-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-acetamide,  
N-[2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-4-methylphenyl]-acetamide, or  
N-[2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-acetamide;

or a pharmaceutically acceptable salt thereof.

29. (Previously Presented) The compound of Claim 28 of the formula Ia:



Ia


wherein

R<sup>2</sup> is selected from the group consisting of:

- (1) hydrogen,  
(2) -C<sub>1-6</sub>alkyl,  
(3) -O-C<sub>1-6</sub>alkyl,  
(4) halo,  
(5) hydroxyl,  
(6) -NO<sub>2</sub>, and  
(7) phenyl;

or a pharmaceutically acceptable salt thereof.


30. (Previously Presented) The compound of Claim 28 of the formula Ib:



Ib

or a pharmaceutically acceptable salt thereof.


31. (Previously Presented) The compound of Claim 28 of the formula Ic:



Ic

or a pharmaceutically acceptable salt thereof.


32. (Previously Presented) The compound of Claim 28 of the formula Id:



Id

or a pharmaceutically acceptable salt thereof.


33. (Previously Presented) The compound of Claim 28 of the formula Ie:



Ie

or a pharmaceutically acceptable salt thereof.

34. (Previously Presented) The compound of Claim 28 of the formula If:



If

or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The compound of Claim 28 wherein R<sup>1</sup> is hydrogen.

36. (Currently Amended) The compound of Claim 28 herein R<sup>2</sup> is halogen.

37. (Previously Presented) The compound of Claim 28 wherein R<sup>2</sup> is fluoro.

38. (Previously Presented) The compound of Claim 28 wherein R<sup>2</sup> is chloro.

39. (Previously Presented) The compound of Claim 28 wherein R<sup>2</sup> is bromo.

40. (Previously Presented) The compound of Claim 28 wherein R<sup>2</sup> is methyl.

41. (Previously Presented) The compound of Claim 28 wherein R<sup>3</sup> is phenyl, which is unsubstituted or substituted with one or more substituents independently selected from:

- (a) -C<sub>1-6</sub>alkyl,
- (b) -O-C<sub>1-6</sub>alkyl,
- (c) halo,
- (d) hydroxy,
- (e) trifluoromethyl,
- (f) -OCF<sub>3</sub>;
- (g) -CO<sub>2</sub>-C<sub>1-6</sub>alkyl,
- (h) -NH<sub>2</sub>,
- (i) -NH-C<sub>1-6</sub>alkyl,
- (j) -CONH<sub>2</sub>, and
- (k) -CONH-C<sub>1-6</sub>alkyl.

42. (Previously Presented) The compound of Claim 28 wherein R<sup>3</sup> is phenyl, which is unsubstituted or substituted with hydroxy, halo, -CONHC<sub>1-6</sub>alkyl or -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

43 (Previously Presented) The compound of Claim 28 wherein R<sup>3</sup> is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, furanyl or thienyl.

44. (Previously Presented) The compound of Claim 28 wherein R<sup>4</sup> and R<sup>5</sup> are joined together to form a phthalimidyl ring.

45. (Previously Presented) The compound of Claim 28 wherein R<sup>5</sup> is hydrogen or C<sub>1-6</sub>alkyl.

46. (Previously Presented) The compound of Claim 28 wherein R<sup>6</sup> is hydrogen.

47. (Previously Presented) The compound of Claim 28 wherein n is 1.

48. (Previously Presented) A compound which is selected from the group consisting of:

N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide;

N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyrimidine-2-carboxamide;



N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide;  
2-[(2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl)amino)carbonyl]phenyl;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-2-hydroxybenzamide;  
2-chloro-N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}benzamide;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-2-fluorobenzamide;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}benzamide;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-3-fluorophenyl}-3,5-difluorobenzamide;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-3-methoxybenzamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-methylbenzamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-furamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-5-methylisoxazole-3-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}cyclohexanecarboxamide;  
N-{5-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}cyclohexanecarboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1-methyl-1H-imidazole-2-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1,3-thiazole-4-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-3-hydroxypyridine-2-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}imidazo[2,1-b][1,3]thiazole-6-carboxamide;  
N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-1,2,5-thiadiazole-3-carboxamide;  
N-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-methoxyphenyl}pyridine-2-carboxamide;  
N-{4-bromo-2-[(4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;  
N-{4-chloro-2-[(2,5-dioxo-3-phenyl-2,5-dihydro-1H-pyrrol-1-yl)methyl]phenyl}pyridine-2-carboxamide;  
N-{4-chloro-2-[(4-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;  
N-{4-chloro-2-[(5,6-dimethyl-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;  
N-{4-chloro-2-[(5-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-chloro-2-[(5-ethoxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{5-bromo-3-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]pyridin-2-yl}pyridine-2-carboxamide;

N-{4-chloro-2-[(5-hydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-bromo-2-[(5-fluoro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-bromo-2-[(5-ethoxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-bromo-2-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-bromo-2-[(4,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{2-[(4,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-fluorophenyl}pyridine-2-carboxamide;

N-{2-[(5,6-dichloro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-fluorophenyl}pyridine-2-carboxamide;

N-{4-fluoro-2-[(5-nitro-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{4-bromo-2-[(4-methyl-1,3-dioxo-3,4,5,6-tetrahydrocyclopenta[c]-pyrrol-2(1H)-yl)methyl]phenyl}pyridine-2-carboxamide;

N-{5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzyl}pyridine-2-carboxamide;

N-(4-bromo-2-[(2-fluorobenzoyl)amino]methyl)phenylpyridine-2-carboxamide;

N-{5-bromo-2-[(pyridin-2-ylcarbonyl)amino]benzyl}pyridine-2-carboxamide;

N-[4-bromo-2-([2-(trifluoromethyl)benzoyl]amino)methyl]phenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,5-dichlorobenzoyl)(ethyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(2-[(4-butoxybenzoyl)(ethyl)amino]methyl)-4-chlorophenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,5-dimethoxybenzoyl)(ethyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,4-dichlorobenzoyl)(ethyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,5-dichlorobenzoyl)(isobutyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,5-dimethoxybenzoyl)(isobutyl)amino]methyl)phenylpyridine-2-carboxamide;

N-{5-fluoro-2-[(pyridin-2-ylcarbonyl)amino]benzyl}quinoxaline-2-carboxamide;

N-(2-[(4-butoxybenzoyl)amino]methyl)-4-fluorophenylpyridine-2-carboxamide;

N-(4-bromo-2-[(3-methoxybenzoyl)(methyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(4-chloro-2-[(3,5-dichlorobenzoyl)(methyl)amino]methyl)phenylpyridine-2-carboxamide;

N-(2-[[3,5-bis(trifluoromethyl)benzoyl](methyl)amino]methyl)-4-chlorophenylpyridine-2-carboxamide;

N-[4-chloro-2-[(3,5-dichlorobenzoyl)[2-(dimethylamino)ethyl]amino]methyl]phenylpyridine-2-carboxamide;


N-[2-(benzoylamino)-5-bromobenzyl]-N,3,5-trimethylbenzamide;  
 N-(4-bromo-2-[[[(3,5-dichlorobenzoyl)(methyl)amino]methyl]-phenyl]pyridine-2-carboxamide;  
 N-(4-bromo-2-[[[(3,4-difluorobenzoyl)(methyl)amino]methyl]phenyl]-pyridine-2-carboxamide;  
 N-(4-bromo-2-[[[(2,4-difluorobenzoyl)(methyl)amino]methyl]phenyl]-pyridine-2-carboxamide;  
 N-(4-bromo-2-[[[(3,4-dichlorobenzoyl)(methyl)amino]methyl]phenyl]-pyridine-2-carboxamide;  
 N-[4-chloro-2-({methyl[2-(trifluoromethyl)benzoyl]amino}methyl)-phenyl]pyridine-2-carboxamide;  
 N-(4-chloro-2-[[[(3,4-dichlorobenzoyl)(methyl)amino]methyl]-phenyl]pyridine-2-carboxamide;  
 or a pharmaceutically acceptable salt thereof.

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (New) A compound which is:



or a pharmaceutically acceptable salt thereof.

53. (New) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 28 or a pharmaceutically acceptable salt thereof.

54. (New) A method for potentiation or inhibition of metabotropic glutamate receptor activity in a mammal which comprises the administration of an effective amount of the compound of Claim 28 or a pharmaceutically acceptable salt thereof.

55. (New) A method for treating, controlling, or reducing the risk of schizophrenia in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of a compound of Claim 28 or a pharmaceutically acceptable salt thereof.